Transdermal News: Breaking Transdermal News, Comments and Articles. - Page: 2

Purdue Pharma L.P. Announces Resolution of OxyContin® (oxycodone HCl controlled-release) Tablets CII Patent Lawsuit with Actavis, Inc.

STAMFORD, Conn., April 26, 2013 /PRNewswire/ -- Purdue Pharma L.P. and Actavis, Inc. announced today that the companies have agreed to resolve the patent infringement lawsuits between them now pending in the United States District Court for the Southern District of New York concerning certain Purdue patents, including patents for abuse-deterrent technology, protecting OxyContin® (oxycodone HC...

[Radius Health] closes $43mm PIPE

Five months after withdrawing its proposed IPO, [Radius Health Inc.] (has had public status since May 2011 through reverse merger with MPM Acquisition Corp.; developing drugs for women’s health and osteoporosis) has raised $43mm in its fourth finan...

Radius raises $43 million in series B

Radius Health Inc. (Cambridge, Mass.) raised $43 million in a series B round led by new investor F2 Biosciences. Existing investors Biotech Growth; MPM Capital; Brookside Capital; MPM Bio IV NVS Strategic Fund; and BB Biotech AG also participated. F2...

NuPathe Announces Allowance of U.S. Patent Application for NP201

CONSHOHOCKEN, PA -- (Marketwired) -- 04/25/13 -- NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 12/074,101 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to a biodegradable polymer implant capable of delivering a dopamine modulating co...

DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call

CUPERTINO, Calif., April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live...

Cabot Corporation Technology Leader Wendy Pryce Lewis Selected for Mass High Tech’s 2013 Women to Watch

Cabot Corporation (NYSE: CBT) announces Wendy Pryce Lewis will be honored by Mass High Tech as one of the 2013 Women to Watch at an awards ceremony to be held at the Westin Boston Waterfront Hotel in Boston on May 9. Mass High Tech’s Women to Watch recognizes “women in tech and life sciences who are go-getters, hardworking, inspirationa...

Research report on global drug delivery technology market

The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017", a...

Drug Delivery Technology Market worth $224.2 Billion By 2017

DALLAS, April 22, 2013 /PRNewswire/ -- The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017", analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, an...

DURECT submits NDA for pain relief treatment

DURECT Corporation has submitted a New Drug Application to the FDA for its investigational product POSIDUR (SABER-Bupivacaine), a post-operative pain relief depot that utilises DURECT’s patented SABER technology to deliver bupivacaine and is design...

Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone

Investigational Treatment for Mild Traumatic Brain Injury to be Studied in Phase I Trial Later This Year BANGKOK, April 18, 2013 /PRNewswire-USNewswire/ -- Besins Healthcare (Besins) and Shin Nippon Biomedical Laboratories (SNBL), a global leader in hormonal products, announced today that they have completed a licensing agreement to use SNBL's proprietary intranasal drug delivery system,...

DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)

CUPERTINO, Calif., April 16, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational product POSIDUR (SABER®-Bupivacaine).  POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER technology to deliver bupivacaine and is des...

Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.

FREMONT, Calif., April 15, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS), a leading com...

BMI Doesn't Seem to Dull Efficacy of Opioid Patch

(MedPage Today) -- FORT LAUDERDALE, Fla. -- The pain-relieving effect of the buprenorphine transdermal medication system didn't seem to be altered by a patient's body mass index (BMI), researchers said here.

AAPS PharmSciTech: A Preformulation Strategy for the Selection of Penetration Enhancers for a Transungual Formulation

Type: Original PaperOnychomycosis is associated with the cutaneous fungal infection of the nail and the nail folds (skin surrounding the nail). It is therefore important to target drug delivery into the nail folds along with nail plate and the nail b...

Easton Pharmaceuticals Provides Corporate Update

Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces corporate changes to its management and business product strategy. As a result of various internal differences with business strategy, Easton Pharmaceuticals exe...

Zosano Pharma, Inc. Announces Key Strategic Hire

FREMONT, Calif., April 9, 2013 /PRNewswire/-- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business development, legal, and investor relations a...

Radiant Research Launches New Website to Highlight Achievements in Consumer Product Testing

With 20 national research centers, an experienced staff and a database of more than one million subjects, Radiant Research has become an industry leader in complex consumer product trials. Radiant expanded its core business of clinical trials when it established the Consumer Product Testing Division in 2011. Since the launch, Radiant has become a premier r...

Noven Pharmaceuticals files ANDA with FDA for approval of generic version of Exelon

Noven Pharmaceuticals, Inc. today confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage...

Noven Confirms Filing of Abbreviated New Drug Application for Generic Version of Exelon® (Rivastigmine Transdermal System)

Noven Pharmaceuticals, Inc. today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage strengths. Noven’s product, if approved, would be a generic version of Novartis Pharmaceutica...

New Resource For Menopause Has Arrived: Upsher-Smith Debuts Redesigned Divigel® Website

MAPLE GROVE, Minn., April 2, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the launch of its new, enhanced website for Divigel® (estradiol gel) 0.1%, www.divigel.com.  The updated site, with its comforting spa-like feel, delivers comprehensive information to the approximately 70 million women over the age of 50 who may be seeking information about menopause.1&...

FDA loosens restrictions on OTC smoking cessation aids

After reviewing scientific research on the safety of over-the-counter (OTC) nicotine replacement therapies (NRTs), such as gum, lozenges and transdermal patches, the US FDA has decided that some warnings and limitations specified in the directions.....

AAPS PharmSciTech: l-Carvyl Esters as Penetration Enhancers for the Transdermal Delivery of 5-Fluorouracil

Type: Original PaperTo develop effective and safe penetration enhancers, a series of l-carvyl esters, namely, 5-isopropenyl-2-methylcyclohex-2-en-1-yl heptanoate (C-HEP), 5-isopropenyl-2- methylcyclohex-2-en-1-yl octanoate (C-OCT), 5-isopropenyl-2-me...

NuPathe Announces Fourth Quarter and Full Year 2012 Financial Results and Operational Highlights

CONSHOHOCKEN, PA -- (Marketwire) -- 03/26/13 -- NuPathe Inc. (NASDAQ: PATH) today announced financial results for the quarter and full year ended December 31, 2012, as well as recent operational highlights. "Our efforts in 2012 culminated in a major milestone for NuPathe with FDA's approval of ZECUITY, the first and only prescription migraine patch, in January," said Armando Anido, chief executi...

Actavis confirms generic Alzheimer’s patch patent challenge

US generics maker Actavis (formerly Watson) confirmed on 8 March 2013 that it had filed with FDA an amendment to its Abbreviated New Drug Application (ANDA) for rivastigmine transdermal system to include the 13.3 mg per 24 hour dosage strength. Actav...

Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications

NEW YORK, March 22, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") today announced the initiation of a life-cycle management plan as the first phase in their portfolio expansion initiative. As part of this plan, Alliqua is making a number of product changes designed to increase adoption of SilverSeal® and Hydress® dressings. Alliqua intends that these o...